Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis (Q37525093)

20 August 2017

0 references

1 reference

title

Efficacy of killed whole-parasite vaccines in the prevention of leishmaniasis: a meta-analysis (English)

1 reference

20 August 2017

0 references

Peter G Smith

11

0 references

Iraj Sharifi

object named as

Iraj Sharifi

7

0 references

Lawrence H. Moulton

object named as

Lawrence H Moulton

3

0 references

Marcel Tanner

4

object named as

Marcel Tanner

1 reference

20 August 2017

Sassan Noazin

1

1 reference

20 August 2017

Ali Khamesipour

2

1 reference

20 August 2017

Kiumarss Nasseri

5

1 reference

20 August 2017

Farrokh Modabber

6

1 reference

20 August 2017

E A G Khalil

8

1 reference

20 August 2017

Ivan Dario Velez Bernal

9

1 reference

20 August 2017

Carlos M F Antunes

10

1 reference

20 August 2017

language of work or name

English

0 references

publication date

18 June 2009

1 reference

20 August 2017

1 reference

20 August 2017

27

1 reference

20 August 2017

35

1 reference

20 August 2017

4747-4753

1 reference

Leishmaniasis: new approaches to disease control

20 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

Visceral leishmaniasis in Brazil: revisiting paradigms of epidemiology and control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

A policy for leishmaniasis with respect to the prevention and control of drug resistance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

Leishmaniasis--current chemotherapy and recent advances in the search for novel drugs

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

Drug resistance in leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

Refractoriness to the treatment of sodium stibogluconate in Indian kala-azar field isolates persist in in vitro and in vivo experimental models

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

Unresponsiveness to Glucantime treatment in Iranian cutaneous leishmaniasis due to drug-resistant Leishmania tropica parasites

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

Treatment of visceral leishmaniasis with sodium stibogluconate in Sudan: management of those who do not respond.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

Leishmanization: use of an old method for evaluation of candidate vaccines against leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

Vaccine for prophylaxis and immunotherapy, Brazil

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

Leishmaniasis: current status of vaccine development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: safety, immunogenicity, and efficacy during the first 12 months of follow-up

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

Comparative safety and immunogenicity trial of two killed Leishmania Major vaccines with or without BCG in human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

Stepwise safety trial of a killed Leishmania vaccine in Iran

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: a randomised, double-blind, BCG-controlled trial in Sudan.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

First generation leishmaniasis vaccines: a review of field efficacy trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

Failure of a killed Leishmania amazonensis vaccine against American cutaneous leishmaniasis in Colombia.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

Controlled field trials of a vaccine against New World cutaneous leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

Immunochemotherapy for cutaneous leishmaniasis: a controlled trial using killed Leishmania (Leishmania) amazonensis vaccine plus antimonial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against New World cutaneous leishmaniasis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

Assessing heterogeneity in meta-analysis: Q statistic or I2 index?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

The role of BCG in human immune responses induced by multiple injections of autoclaved Leishmania major as a candidate vaccine against leishmaniasis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.05.084

10.1016/J.VACCINE.2009.05.084

7 January 2021

Identifiers

DOI

1 reference

20 August 2017

1 reference